MDL | MFCD00133874 |
---|---|
Molecular Weight | 503.54 |
Molecular Formula | C26H33NO9 |
SMILES | O=C(O)/C=C\C(O)=O.O=C(OCC(C1=CC=CC=C1)(N(C)C)CC)C2=CC(OC)=C(OC)C(OC)=C2 |
Trimebutine maleate is a drug with antimuscarinic and weak mu opioid agonist effects. Target: Opioid Receptor Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain [1]. The major product from drug metabolism of trimebutine in human beings is nor-trimebutine, which comes from removal of one of the methyl groups attached to nitrogen. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract [2, 3].
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT04403087 | Chuncheon Sacred Heart Hospital |
Helicobacter Pylori Infection
|
May 1, 2021 | Phase 4 |
NCT03359499 | Hospital Britanico |
Irritable Bowel Syndrome
|
August 12, 2017 | Phase 2|Phase 3 |
NCT01984931 | CM Chungmu Hospital|Korea United Pharm. Inc. |
Nausea|Vomiting
|
October 2013 | Phase 3 |
NCT02986685 | Xijing Hospital of Digestive Diseases|Ankang City Central Hospital|Shaanxi Provincial People´s Hospital|Baoji Central Hospital|Hanzhong Central Hospital |
Refractory Reflux Esophagitis
|
November 2016 | Phase 4 |
NCT03036111 | Mansoura University |
Hemorrhoids
|
February 1, 2017 | Not Applicable |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : 100 mg/mL ( 198.59 mM ; Need ultrasonic)
H 2 O : 25 mg/mL ( 49.65 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.9859 mL | 9.9297 mL | 19.8594 mL |
5 mM | 0.3972 mL | 1.9859 mL | 3.9719 mL |
10 mM | 0.1986 mL | 0.9930 mL | 1.9859 mL |